204 related articles for article (PubMed ID: 32114681)
1. Neutrophils are mediators of metastatic prostate cancer progression in bone.
Costanzo-Garvey DL; Keeley T; Case AJ; Watson GF; Alsamraae M; Yu Y; Su K; Heim CE; Kielian T; Morrissey C; Frieling JS; Cook LM
Cancer Immunol Immunother; 2020 Jun; 69(6):1113-1130. PubMed ID: 32114681
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer addiction to oxidative stress defines sensitivity to anti-tumor neutrophils.
Costanzo-Garvey DL; Case AJ; Watson GF; Alsamraae M; Chatterjee A; Oberley-Deegan RE; Dutta S; Abdalla MY; Kielian T; Lindsey ML; Cook LM
Clin Exp Metastasis; 2022 Aug; 39(4):641-659. PubMed ID: 35604506
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression.
Alsamraae M; Costanzo-Garvey D; Teply BA; Boyle S; Sommerville G; Herbert ZT; Morrissey C; Dafferner AJ; Abdalla MY; Fallet RW; Kielian T; Jensen-Smith H; deOliveira EI; Chen K; Bettencourt IA; Wang JM; McVicar DW; Keeley T; Yu F; Cook LM
Cancer Lett; 2023 Nov; 579():216468. PubMed ID: 37940068
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
6. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.
Wang W; Yang X; Dai J; Lu Y; Zhang J; Keller ET
Oncogene; 2019 Jun; 38(23):4540-4559. PubMed ID: 30755731
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling.
Tang Y; Pan J; Huang S; Peng X; Zou X; Luo Y; Ren D; Zhang X; Li R; He P; Wa Q
J Exp Clin Cancer Res; 2018 Jul; 37(1):160. PubMed ID: 30021600
[TBL] [Abstract][Full Text] [Related]
9. m
Lang C; Yin C; Lin K; Li Y; Yang Q; Wu Z; Du H; Ren D; Dai Y; Peng X
Clin Transl Med; 2021 Jun; 11(6):e426. PubMed ID: 34185427
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.
Colden M; Dar AA; Saini S; Dahiya PV; Shahryari V; Yamamura S; Tanaka Y; Stein G; Dahiya R; Majid S
Cell Death Dis; 2017 Jan; 8(1):e2572. PubMed ID: 28125091
[TBL] [Abstract][Full Text] [Related]
11. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling.
Luo J; Ok Lee S; Liang L; Huang CK; Li L; Wen S; Chang C
Oncogene; 2014 May; 33(21):2768-78. PubMed ID: 23792449
[TBL] [Abstract][Full Text] [Related]
12. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.
Kfoury Y; Baryawno N; Severe N; Mei S; Gustafsson K; Hirz T; Brouse T; Scadden EW; Igolkina AA; Kokkaliaris K; Choi BD; Barkas N; Randolph MA; Shin JH; Saylor PJ; Scadden DT; Sykes DB; Kharchenko PV;
Cancer Cell; 2021 Nov; 39(11):1464-1478.e8. PubMed ID: 34719426
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner.
Henrich SE; McMahon KM; Plebanek MP; Calvert AE; Feliciano TJ; Parrish S; Tavora F; Mega A; De Souza A; Carneiro BA; Thaxton CS
J Extracell Vesicles; 2020 Dec; 10(2):e12042. PubMed ID: 33408816
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
[TBL] [Abstract][Full Text] [Related]
15. MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway.
Yang Q; Lang C; Wu Z; Dai Y; He S; Guo W; Huang S; Du H; Ren D; Peng X
J Exp Clin Cancer Res; 2019 Sep; 38(1):391. PubMed ID: 31488180
[TBL] [Abstract][Full Text] [Related]
16. BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis.
Seo SI; Gera L; Zhau HE; Qian WP; Iqbal S; Johnson NA; Zhang S; Zayzafoon M; Stewart J; Wang R; Chung LW; Wu D
Clin Cancer Res; 2008 Oct; 14(19):6198-206. PubMed ID: 18829499
[TBL] [Abstract][Full Text] [Related]
17. BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer.
Yin C; Wang M; Wang Y; Lin Q; Lin K; Du H; Lang C; Dai Y; Peng X
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36941015
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
[TBL] [Abstract][Full Text] [Related]
19. [Construction and improvement of animal models with different positional osseous metastasis of prostate cancer in vivo].
Bi YX; Xiao MH; Zhang NN; Li XY; Mao XP; Zhang K; Zhang ZR; Zhao LY
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):590-596. PubMed ID: 28816271
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
Zhang S; Gera L; Mamouni K; Li X; Chen Z; Kucuk O; Wu D
Oncotarget; 2016 May; 7(19):27489-98. PubMed ID: 27050371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
